Novo to Acquire Another Obesity Company; Zealand Receives Priority Review for Dasiglucagon CHI NDA

Two cardiometabolic-related news items have been observed: Embark Laboratories announced that Novo Nordisk acquired the company and its lead obesity asset (view press release); and Zealand announced FDA granted priority review for its dasiglucagon NDA for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age or older with congenital hyperinsulinism (CHI; view press release). Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.